Rg3 in Combination With TACE in Hepatocellular Carcinoma Patients With High Expression of Notch1
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
In order to provide a new option for clinical anti-angiogenesis therapy in hepatoma, a
randomized controlled study is planed to confirm the effect of Rg3 in combination with TACE
on angiogenesis and tumor treatment in advanced hepatocellular carcinoma patients with high
expression of Notch1.